Share Price of Intellect Neurosciences, Inc. (ILNS.OB) Up on Alzheimer’s Drug News
Intellect Neurosciences, Inc., a biotechnology company with several drugs in various stages of development, released more data today regarding it lead Alzheimer’s candidate, OX1 (Oxigon™), which has recently completed a Phase 1b clinical trial. After releasing data in late October showing that the drug was well tolerated and safe at all dosing levels, the Company announced that it has received a pharmacokinetic profile report from a fourteen-day safety trial. OX1 is a unique molecule that is being proven effective at promoting clearance of soluble beta amyloid and also blocks neurotoxicity that is created by free radicals. This neurotoxicity damages synaptic…